Passa al contenuto
Merck
Tutte le immagini(3)

Documenti fondamentali

PRS4065

Sigma-Aldrich

Anti-PD-1 (ab1) antibody produced in rabbit

affinity isolated antibody, buffered aqueous solution

Sinonimo/i:

Anti-CD279, Anti-PDCD1, Anti-Programmed cell death 1

Autenticatiper visualizzare i prezzi riservati alla tua organizzazione & contrattuali


About This Item

Codice UNSPSC:
12352203
NACRES:
NA.41

Origine biologica

rabbit

Coniugato

unconjugated

Forma dell’anticorpo

affinity isolated antibody

Tipo di anticorpo

primary antibodies

Clone

polyclonal

Stato

buffered aqueous solution

PM

predicted mol wt 32 kDa

Reattività contro le specie

mouse, human

tecniche

immunofluorescence: suitable
immunohistochemistry: suitable
indirect ELISA: suitable
western blot: suitable

N° accesso UniProt

Condizioni di spedizione

dry ice

Temperatura di conservazione

−20°C

modifica post-traduzionali bersaglio

unmodified

Informazioni sul gene

human ... PDCD1(5133)

Descrizione generale

PD-1 (programmed death-1) is an immunosuppressive molecule, which is also known as PDCD1 (programmed cell death 1). It is located on chromosome 2q37.3. It is a member of immunoglobulin receptor superfamily.

Immunogeno

a 16 amino acid peptide from near the carboxy-terminus of human PD-1.

Azioni biochim/fisiol

PD-1 (programmed death-1) gene is sensitive to systemic lupus erythematosus (SLE). Polymorphisms in PD-1 may participate in the growth of EOC (epithelial ovarian cancer). It acts as a negative regulator of T cells. It is also responsible for immune escape mediated by tumor cell.

Linkage

The action of this antibody can be blocked using blocking peptide SBP4065.

Stato fisico

Solution in phosphate buffered saline containing 0.02% sodium azide

Esclusione di responsabilità

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

Non trovi il prodotto giusto?  

Prova il nostro Motore di ricerca dei prodotti.

Prodotti correlati

N° Catalogo
Descrizione
Determinazione del prezzo

Raccomandato

N° Catalogo
Descrizione
Determinazione del prezzo

Codice della classe di stoccaggio

12 - Non Combustible Liquids

Classe di pericolosità dell'acqua (WGK)

nwg

Punto d’infiammabilità (°F)

Not applicable

Punto d’infiammabilità (°C)

Not applicable


Scegli una delle versioni più recenti:

Certificati d'analisi (COA)

Lot/Batch Number

Non trovi la versione di tuo interesse?

Se hai bisogno di una versione specifica, puoi cercare il certificato tramite il numero di lotto.

Possiedi già questo prodotto?

I documenti relativi ai prodotti acquistati recentemente sono disponibili nell’Archivio dei documenti.

Visita l’Archivio dei documenti

I clienti hanno visto anche

Slide 1 of 2

1 of 2

A new haplotype of PDCD1 is associated with rheumatoid arthritis in Hong Kong Chinese
Kong EK, et al.
Arthritis and Rheumatism, 52(4), 1058-1062 (2005)
The effect of polymorphisms in PD-1 gene on the risk of epithelial ovarian cancer and patients' outcomes
Li Y, et al.
Gynecologic Oncology, 144(1), 140-145 (2017)
Gang Chen et al.
Nature neuroscience, 20(7), 917-926 (2017-05-23)
Programmed cell death ligand-1 (PD-L1) is typically produced by cancer cells and suppresses immunity through the receptor PD-1 expressed on T cells. However, the role of PD-L1 and PD-1 in regulating pain and neuronal function is unclear. Here we report
Christopher H Cogbill et al.
American journal of clinical pathology, 142(1), 88-98 (2014-06-14)
CD279 expression is used to help identify angioimmunoblastic T-cell lymphoma (AITL) or other T-cell lymphomas of T-follicular helper (TFH) cell origin; however, its utility in assessing lymphoid infiltrates in the bone marrow (BM) is not well established. Immunohistochemistry for CD279
Zhi-Chun Ding et al.
Cancer research, 74(13), 3441-3453 (2014-05-02)
In recent years, immune-based therapies have become an increasingly attractive treatment option for patients with cancer. Cancer immunotherapy is often used in combination with conventional chemotherapy for synergistic effects. The alkylating agent cyclophosphamide (CTX) has been included in various chemoimmunotherapy

Il team dei nostri ricercatori vanta grande esperienza in tutte le aree della ricerca quali Life Science, scienza dei materiali, sintesi chimica, cromatografia, discipline analitiche, ecc..

Contatta l'Assistenza Tecnica.